Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma

• Published in: Biology of sex differences 2023-07, Vol.14 (1), p.46-46, Article 46
• Main Authors: Yuan, Huiyang, Qin, Xin, Yang, Qingya, Liu, Li, Fang, Zhiqing, Fan, Yidong, Xu, Dawei
• Format: Article
• Language: English
• Subjects: Analysis; Biomarkers; Cancer therapies; Carcinoma, Renal cell; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Care and treatment; ccRCC; Cell Cycle Proteins; Clear cell-type renal cell carcinoma; Development and progression; DKC1; Drug resistance; Female; Females; Gender differences; Growth factors; Humans; Kidney cancer; Kidney Neoplasms - drug therapy; Kidney Neoplasms - genetics; Kinases; Medical prognosis; Medicin och hälsovetenskap; Metastasis; Myc protein; Nuclear Proteins; p53 Protein; Patient outcomes; Patients; Ribonucleic acid; RNA; RNA sequencing; RNA-Binding Proteins; Sex; Sex difference; Sex differences; Sunitinib; Sunitinib - therapeutic use; Telomerase; Telomerase - genetics; TERC; Tumor proteins; Tumors; Tyrosine; X chromosomes
• ISSN: 2042-6410; 2042-6410
• DOI: 10.1186/s13293-023-00526-7

Clear cell renal cell carcinoma (ccRCC) displays sex-biased incidence, outcomes, molecular alterations and treatment efficacy; however, clinical managements are largely identical in male and female patients. Moreover, many biomarkers have been identified as predictors for ccRCC outcomes and response to therapeutic drugs, such as multitargeted tyrosine-kinase receptor (TKR) inhibitors, but little is known about their sex-specificity. Dyskerin (DKC1), encoded by the DKC1 gene within Xq28, is a telomerase co-factor stabilizing telomerase RNA component (TERC) and overexpressed in various cancers. Here, we determined whether DKC1 and/or TERC affect ccRCC sex-differentially. DKC1 and TERC expression in primary ccRCC tumors was assessed using RNA sequencing and qPCR. DKC1 association with molecular alterations and overall or progression-free survival (OS or PFS) was analyzed in the TCGA cohort of ccRCC. The IMmotion 151 and 150 ccRCC cohorts were analyzed to evaluate impacts of DKC1 and TERC on Sunitinib response and PFS. DKC1 and TERC expression was significantly upregulated in ccRCC tumors. High DKC1 expression predicts shorter PFS independently in female but not male patients. Tumors in the female DKC1-high group exhibited more frequent alterations in PIK3CA, MYC and TP53 genes. Analyses of the IMmotion 151 ccRCC cohort treated with the TKR inhibitor Sunitinib showed that female patients in the DKC1-high group was significantly associated with lower response rates (P = 0.021) accompanied by markedly shortened PFS (6.1 vs 14.2 months, P = 0.004). DKC1 and TERC expression correlated positively with each other, and higher TERC expression predicted poor Sunitinib response (P = 0.031) and shorter PFS (P = 0.004), too. However, DKC1 rather than TERC acted as an independent predictor (P